These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 7008748)

  • 1. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of gemfibrozil on serum lipids in diabetic patients.
    Konttinen A; Kuisma I; Ralli R; Pohjola S; Ojala K
    Ann Clin Res; 1979 Dec; 11(6):240-5. PubMed ID: 398183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC).
    Børresen AL; Berg K; Dahlén G; Gillnäs T; Ericson C
    Artery; 1981; 9(1):77-86. PubMed ID: 7018466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.
    Olsson AG; Rössner S; Walldius G; Carlson LA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):28-31. PubMed ID: 190607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of lipoprotein changes during gemfibrozil treatment.
    Janus ED; Costa D; Ononogbu IC; Lewis B
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):76-7. PubMed ID: 1019156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemfibrozil on serum lipids.
    Samuel P
    Am J Med; 1983 May; 74(5A):23-7. PubMed ID: 6573843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
    Vessby B; Lithell H; Boberg J; Hellsing K; Werner I
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):32-7. PubMed ID: 798194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil, lipids, and coronary risk.
    Rifkind BM
    N Engl J Med; 1987 Nov; 317(20):1279-81. PubMed ID: 3313042
    [No Abstract]   [Full Text] [Related]  

  • 15. A long-term trial of gemfibrozil in the treatment of hyperlipidaemias.
    Eisalo A; Manninen V
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):49-52. PubMed ID: 798198
    [No Abstract]   [Full Text] [Related]  

  • 16. Gemfibrozil in a group of diabetics.
    de Salcedo I; Gorringe AL; Silva JL; Santos JA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):64-70. PubMed ID: 1019155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report.
    Honorato J; Masso RM; Purroy A
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):78-9. PubMed ID: 798200
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
    Weintraub MS; Eisenberg S; Breslow JL
    J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.